Skip to Content

Proposed Rule

Regulatory New Drug Review: Solutions for Study Data Exchange Standards; Notice of Meeting; Request for Comments; Correction

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

ACTION:

Announcement of meeting; request for comments; correction.

SUMMARY:

The Food and Drug Administration (FDA) is correcting a document that appeared in the Federal Register of August 14, 2012 (77 FR 48491). The document announced a meeting entitled “Regulatory New Drug Review: Solutions for Study Data Exchange Standards.” The document was published with an incorrect email address. This document corrects that error.

FOR FURTHER INFORMATION CONTACT:

Ron Fitzmartin, Office of Planning & Informatics, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 1160, Silver Spring, MD 20993-0002, 301-796-5333, FAX: 301-847-8443, email: CDERDataStandards@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

In FR Doc. 2012-19748, appearing on page 48491 in the Federal Register of August 14, 2012, the following corrections are made:

1. On page 48491, in the first column, in the FOR FURTHER INFORMATION CONTACT section, the email address “CDERDataStandards@hhs.fda.gov” is corrected to read “CDERDataStandards@fda.hhs.gov.”

2. On page 48491, in the second column, in the SUPPLEMENTARY INFORMATION section, under “Registration,” the email address “CDERDataStandards@hhs.fda.gov” is corrected to read “CDERDataStandards@fda.hhs.gov.”

Dated: September 11, 2012.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2012-22793 Filed 9-14-12; 8:45 am]

BILLING CODE 4160-01-P